Institutional members access full text with Ovid®

Share this article on:

Patch Tests With Fragrance Mix II and Its Components

Pónyai, Györgyi MD, PhD*; Németh, Ilona*; Altmayer, Anita MD; Nagy, Gabriella MD; Irinyi, Beatrix MD, PhD§; Battyáni, Zita MD, PhD∥¶; Temesvári, Erzsébet MD, PhD*; on behalf of the Hungarian Contact Dermatitis Group

doi: 10.1097/DER.0b013e31824a6104

Background: Fragrance mix II (FM II) was initiated to detect contact hypersenstitivity (CH) to fragrances that could not have been identified previously.

Objective: The aim of this multicenter study was to map the frequency of CH to FM II and its components in Hungary.

Methods: Six centers participated in the survey from 2009 to 2010. A total off 565 patients (434 women and 131 men) with former skin symptoms provoked by scented products were patch tested. The tests were performed with Brial GmbH D-Greven allergens. In the environmental patch test series, FM II, FM I, Myroxylon pereirae, colophonium, wood-tar mix, propolis, and sesquiterpene lactone mix were tested as fragrance allergens. The FM II components (citral, farnesol, coumarin, citronellol, α-hexyl-cinnamaldehyde, and hydroxy-isohexyl-3-cyclohexene-carboxaldehyde [Lyral]) were also tested.

Results: Contact hypersenstitivity to any fragrances was detected in 28.8%, to FM II in 17.2% of the patients. Contact hypersenstitivity to hydroxy-isohexyl-3-cyclohexene-carboxaldehyde was observed in 7.3%, to coumarin in 5.1%, to α-hexyl-cinnamaldehyde in 3.5%, to citral in 3.4%, to farnesol in 2.5%, and to citronellol in 1.2%. Of the FM II–positive cases, 48.4% showed isolated CH reaction.

Conclusions: The frequency of CH to FM II is 17.2% in the tested, selected Hungarian population. The CH to FM II and its components could not have been revealed without the present test materials.

From the *Department of Dermatology, Venerology, and Dermato-oncology, Semmelweis University, Budapest; †Department of Dermatology and Allergy of the Szent-Györgyi Albert Clinical Centre, Szeged University of Sciences, Szeged; ‡Centre of Dermatology, Semmelweis Medical Centre of Miskolc, Miskolc; §Department of Dermatology, Centre for Medicine and Medical Sciences, Faculty of General Medicine, University of Debrecen, Debrecen; ∥Department of Dermatology, Venerology and Dermato-oncology, Pécs Medical University, Pécs; and ¶Department of Dermatology, Kaposi Mór Teaching Hospital, Kaposvár, Hungary.

Address reprint requests to Györgyi Pónyai, MD, PhD, Department of Dermatology, Venerology, and Dermato-oncology, Semmelweis University, Budapest, Hungary. E-mail:

The authors have no funding or conflicts of interest to declare.

©2012American Contact Dermatitis Society, All Right Reserved
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website